文献速递分子诊断质量管理与危急值

使用Cq值定量生物样本核酸的危险:COVID-19的教训

The Dangers of Using Cq to Quantify Nucleic Acid in Biological Samples: A Lesson From COVID-19.
PubMed 文献 · Clin Chem · 2021-01-01

该研究分析了英国、比利时和韩国3家临床实验室超过6000例患者的SARS-CoV-2 RNA定量分布(Cq值和 copies/mL),评估Cq截断值对临床灵敏度的影响,并利用2020年6/7月INSTAND外部质量评估方案材料估计实验室报告的 copies/mL 及给定Cq下 copies/mL 的变异。结果显示,采用WHO建议的Cq截断值25时临床灵敏度降至约16%;模拟检测限10^6 copies/mL时灵敏度降至约27%;给定Cq值的实验室间 copies/mL 变异>1000倍(99% CI)。结论推荐不应使用Cq值设定临床截断值或诊断性能目标,而应使用基于校准的拷贝数单位。

要点

  • Cq值实验室间重现性差,给定Cq下 copies/mL 变异>1000倍(99% CI)。
  • 采用Cq截断值25时临床灵敏度降至约16%。
  • 模拟检测限10^6 copies/mL时临床灵敏度降至约27%。

核心结论

  • 推荐不应使用Cq值设定临床截断值或诊断性能目标,因其实验室间重现性差。
  • 基于校准的拷贝数单位(已在病毒学其他领域使用)提供更可重现的替代方案。
  • 诊断性能可能随有效再生数变化,评估或部署诊断测试时需考虑不同时间患者人群的差异。

研究设计与样本

  • 分析来自英国、比利时和韩国3家临床实验室超过6000例患者的SARS-CoV-2 RNA定量分布(Cq和copies/mL)。
  • 评估Cq截断值对临床灵敏度的影响。
  • 使用2020年6/7月INSTAND外部质量评估方案SARS-CoV-2材料估计实验室报告的copies/mL及给定Cq下copies/mL的变异。

主要发现

  • 采用WHO建议的Cq截断值25时,临床灵敏度降至约16%。
  • 模拟检测限10^6 copies/mL时,临床灵敏度降至约27%。
  • 给定Cq值的实验室间copies/mL变异>1000倍(99% CI)。

关键数值与推荐

  • WHO建议的Cq截断值25对应临床灵敏度约16%。
  • 模拟检测限10^6 copies/mL对应临床灵敏度约27%。
  • 给定Cq值下实验室间copies/mL变异>1000倍(99% CI)。

临床怎么用

  • 不应使用Cq值设定临床截断值或诊断性能目标。
  • 建议使用基于校准的拷贝数单位(copies/mL)进行核酸定量。
  • 评估或部署诊断测试时需考虑不同时间患者人群的差异及有效再生数变化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA quantities, measured by reverse transcription quantitative PCR (RT-qPCR), have been proposed to stratify clinical risk or determine analytical performance targets. We investigated reproducibility and how setting diagnostic cutoffs altered the clinical sensitivity of coronavirus disease 2019 (COVID-19) testing. METHODS: Quantitative SARS-CoV-2 RNA distributions [quantification cycle (Cq) and copies/mL] from more than 6000 patients from 3 clinical laboratories in United Kingdom, Belgium, and the Republic of Korea were analyzed. Impact of Cq cutoffs on clinical sensitivity was assessed. The June/July 2020 INSTAND external quality assessment scheme SARS-CoV-2 materials were used to estimate laboratory reported copies/mL and to estimate the variation in copies/mL for a given Cq. RESULTS: When the WHO-suggested Cq cutoff of 25 was applied, the clinical sensitivity dropped to about 16%. Clinical sensitivity also dropped to about 27% when a simulated limit of detection of 106 copies/mL was applied. The interlaboratory variation for a given Cq value was >1000 fold in copies/mL (99% CI). CONCLUSION: While RT-qPCR has been instrumental in the response to COVID-19, we recommend Cq (cycle threshold or crossing point) values not be used to set clinical cutoffs or diagnostic performance targets due to poor interlaboratory reproducibility; calibrated copy-based units (used elsewhere in virology) offer more reproducible alternatives. We also report a phenomenon where diagnostic performance may change relative to the effective reproduction number. Our findings indicate that the disparities between patient populations across time are an important consideration when evaluating or deploying diagnostic tests. This is especially relevant to the emergency situation of an evolving pandemic.

来源:Clin Chem,查看原文。版权归原作者所有。

引用

  1. Evans D, Cowen S, Kammel M, et al. The Dangers of Using Cq to Quantify Nucleic Acid in Biological Samples: A Lesson From COVID-19. Clin Chem. 2021. PMID: 34633030. doi:10.1093/clinchem/hvab219

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。